{"denoms":[{"counts":[{"groupId":"BG000","value":"226"},{"groupId":"BG001","value":"228"},{"groupId":"BG002","value":"454"}],"units":"Participants"}],"groups":[{"description":"Carfilzomib was administered twice-weekly intravenously as a 10 ± 5 minute infusion using an infusion pump on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The dose was 20 mg/m\\^2 on Days 1 and 2 of Cycle 1 and 27 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"BG000","title":"Twice-weekly KRd 20/27 mg/m^2"},{"description":"Carfilzomib was administered once-weekly intravenously as a 30 ± 5 minute infusion using an infusion pump on Days 1, 8, and 15 of each 28-day cycle. The dose was 20 mg/m\\^2 on Day 1 of Cycle 1 and 56 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"BG001","title":"Once-weekly KRd 20/56 mg/m^2"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.2","value":"64.0"},{"groupId":"BG001","spread":"8.4","value":"63.7"},{"groupId":"BG002","spread":"8.3","value":"63.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"218"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"236"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"16"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"213"},{"groupId":"BG001","value":"215"},{"groupId":"BG002","value":"428"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"21"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"209"},{"groupId":"BG001","value":"209"},{"groupId":"BG002","value":"418"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"13"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"402"}],"title":"Stage 1 or 2"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"52"}],"title":"Stage 3"}]}],"description":"ISS stage classification at study entry per interactive voice/web response system for randomization. Stage 1: serum beta-2 microglobulin \\< 3.5 mg/L and serum albumin ≥ 3.5 g/dL; Stage 2: serum beta-2 microglobulin \\< 3.5 mg/L and serum albumin \\< 3.5 g/dL or serum beta-2 microglobulin 3.5 - \\< 5.5 mg/L irrespective of the serum albumin; Stage 3: serum beta-2 microglobulin ≥ 5.5 mg/L.","paramType":"COUNT_OF_PARTICIPANTS","title":"Original ISS Stage at Study Entry","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"164"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"143"},{"groupId":"BG002","value":"290"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Lenalidomide Treatment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"218"},{"groupId":"BG001","value":"214"},{"groupId":"BG002","value":"432"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"22"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Proteasome Inhibitor Treatment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"38"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"209"},{"groupId":"BG001","value":"207"},{"groupId":"BG002","value":"416"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Anti-CD38 Treatment","unitOfMeasure":"Participants"}]}